Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.
Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
In a sign of continued corporate interest in the regenerative and cell therapy area in Japan, Shionogi has acquired rights in this market to a novel cirrhosis treatment being developed by Rohto.
Takeda is to close down and relocate one of its main US sites, with unspecified job losses, as it plans post-Shire restructuring, while in Japan vocal opposition to the acquisition rises.
Some three and a half years after its formation, Japan’s Agency for Medical R&D (AMED) is continuing its efforts to “de-Balkanize” academic research in the country, and to foster closer health research cooperation between government, academia and industry. While progress has been made, particularly in the genomics area, challenges still linger, its president concedes.